We posit that VT02956 inhibits the growth of ER+ breast cancer cells, at least in part, due to the repression of ESR1. Next, we performed a 3D drug killing assay using established primary ER+ BTOs (Fig. 6a). Here, ESR1 is linked to breast cancer.